High-dose Aricept approved in US for moderate to severe Alzheimer's
This article was originally published in Scrip
Executive Summary
The US FDA has approved a high-dose, sustained-release formulation of Eisai's acetylcholinesterase inhibitor Aricept (donepezil) for the treatment of moderate to severe Alzheimer's disease.